On Monday, the Food and Drug Administration will host its first formal discussion about fecal microbiome transplants in years — less than a week after a paper in the New England Journal of Medicine disclosed new details about the first death ever conclusively linked to the procedure, often abbreviated to FMT.
The Monday meeting, which will be happening at the FDA’s headquarters in White Oak, Md., will cover the safety and effectiveness of FMT as a treatment for repeated (and potentially fatal infections) of Clostridium difficile bacteria.
About the Author Reprints
